Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
Authors
Keywords
-
Journal
MOLECULES
Volume 24, Issue 18, Pages 3214
Publisher
MDPI AG
Online
2019-09-05
DOI
10.3390/molecules24183214
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
- (2019) Christopher J. D. Wallis et al. JAMA Oncology
- Sex hormones and anticancer immunity
- (2019) Berna C. Özdemir et al. CLINICAL CANCER RESEARCH
- The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex
- (2019) Shixiang Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis
- (2019) Fabio Conforti et al. JNCI-Journal of the National Cancer Institute
- Sex Differences in Tolerability to Anti‐Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non‐Small Cell Lung Cancer: Are We All Equal?
- (2019) Narjust Duma et al. ONCOLOGIST
- Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non‐small cell lung cancer
- (2019) Chengdi Wang et al. Cancer Medicine
- Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
- (2018) Yingcheng Wu et al. INTERNATIONAL JOURNAL OF CANCER
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
- (2018) Fabio Conforti et al. LANCET ONCOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer
- (2018) Shixiang Wang et al. ONCOGENE
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
- (2018) Diana Miao et al. NATURE GENETICS
- Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
- (2018) Peng Jiang et al. NATURE MEDICINE
- Sex Differences in Cancer Driver Genes and Biomarkers
- (2018) Constance H. Li et al. CANCER RESEARCH
- Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
- (2018) Antonino Grassadonia et al. Journal of Clinical Medicine
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
- (2017) Ramaswamy Govindan et al. JOURNAL OF CLINICAL ONCOLOGY
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
- (2017) Teresa Davoli et al. SCIENCE
- The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
- (2017) Andrea Botticelli et al. Oncotarget
- Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
- (2016) Haidong Tang et al. CANCER CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer
- (2016) Takehito Shukuya et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
- (2016) F Stephen Hodi et al. LANCET ONCOLOGY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of ultra-deep targeted sequencing reveals mutation burden is associated with gender and clinical outcome in lung adenocarcinoma
- (2016) Dakai Xiao et al. Oncotarget
- Variation in serum biomarkers with sex and female hormonal status: implications for clinical tests
- (2016) Jordan M. Ramsey et al. Scientific Reports
- SeXX Matters in Infectious Disease Pathogenesis
- (2016) Landon G. vom Steeg et al. PLoS Pathogens
- Intestinal Microbiota Is Influenced by Gender and Body Mass Index
- (2016) Carmen Haro et al. PLoS One
- Gender Disparity and Mutation Burden in Metastatic Melanoma
- (2015) Sameer Gupta et al. JNCI-Journal of the National Cancer Institute
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Gender Disparity and Mutation Burden in Metastatic Melanoma
- (2015) Sameer Gupta et al. JNCI-Journal of the National Cancer Institute
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of Autoimmunity
- (2013) J. G. M. Markle et al. SCIENCE
- Chromosome Y Regulates Survival Following Murine Coxsackievirus B3 Infection
- (2012) Laure K. Case et al. G3-Genes Genomes Genetics
- Sex Disparities in Cancer Mortality and Survival
- (2011) M. B. Cook et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sex differences in autoimmune diseases
- (2011) Rhonda Voskuhl Biology of Sex Differences
- Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses
- (2010) Matthew D. Morse et al. HUMAN IMMUNOLOGY
- B7-H1-Dependent Sex-Related Differences in Tumor Immunity and Immunotherapy Responses
- (2010) P.-Y. Lin et al. JOURNAL OF IMMUNOLOGY
- Sex bias in neuroscience and biomedical research
- (2010) Annaliese K. Beery et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sex Disparities in Cancer Incidence by Period and Age
- (2009) M. B. Cook et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Estrogen directly activates AID transcription and function
- (2009) Siim Pauklin et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Clinical significance of cancer/testis antigens expression in patients with non-small cell lung cancer
- (2009) Yoshiki Shigematsu et al. LUNG CANCER
- Sex Differences in Autoimmune Disease from a Pathological Perspective
- (2008) DeLisa Fairweather et al. AMERICAN JOURNAL OF PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now